Co-Authors
This is a "connection" page, showing publications co-authored by Thomas Lecompte and Yves Gruel.
Connection Strength
0.273
-
Fatal exacerbation of ChadOx1-nCoV-19-induced thrombotic thrombocytopenia syndrome after initial successful therapy with intravenous immunoglobulins - a rational for monitoring immunoglobulin G levels. Haematologica. 2021 08 12.
Score: 0.060
-
Hypotheses behind the very rare cases of thrombosis with thrombocytopenia syndrome after SARS-CoV-2 vaccination. Thromb Res. 2021 07; 203:163-171.
Score: 0.059
-
[Management of the thrombotic risk associated with COVID-19: what is the role of the hemostasis laboratory?] Ann Biol Clin (Paris). 2020 10 01; 78(5):471-481.
Score: 0.057
-
Management of antiplatelet therapy for non-elective invasive procedures or bleeding complications: Proposals from the French Working Group on Perioperative Haemostasis (GIHP) and the French Study Group on Thrombosis and Haemostasis (GFHT), in collaboration with the French Society for Anaesthesia and Intensive Care (SFAR). Arch Cardiovasc Dis. 2019 Mar; 112(3):199-216.
Score: 0.050
-
Management of antiplatelet therapy in patients undergoing elective invasive procedures. Proposals from the French Working Group on perioperative haemostasis (GIHP) and the French Study Group on thrombosis and haemostasis (GFHT). In collaboration with the French Society for Anaesthesia and Intensive Care Medicine (SFAR). Anaesth Crit Care Pain Med. 2018 Aug; 37(4):379-389.
Score: 0.047